Clinical Trial News and Research

RSS

ATHENA develops surrogate organ system for toxicity testing

Creating surrogate human organs, coupled with insights from highly sensitive mass spectrometry technologies, a new project is on the brink of revolutionizing the way we screen new drugs and toxic agents.

29 Mar 2014

RXi Pharmaceuticals provides business update, reports Q4 and full year 2013 financial results

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today reported its financial results for the full year 2013, and provided a business update.

29 Mar 2014

Two doses of HPV-16/18 AS04-adjuvanted vaccine Cervarix non-inferior to three-doses

A recent study in the journal Human Vaccines & Immunotherapeutics, showed that two doses of the HPV-16/18 AS04-adjuvanted vaccine Cervarix (GlaxoSmithKline) are non-inferior to three-doses in the current schedule.

29 Mar 2014

Idera Pharmaceuticals reports positive top-line results from Phase 2 trial of IMO-8400

Idera Pharmaceuticals, Inc. today announced positive top-line data from its randomized, double-blind, placebo controlled Phase 2 trial of IMO-8400 in 32 patients with moderate-to-severe plaque psoriasis.

28 Mar 2014

ADMA Biologics reports consolidated net loss of $15.5M in 2013

ADMA Biologics, Inc., a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced its financial results for the year ended December 31, 2013 and provided recent company developments as well as anticipated milestones for 2014.

28 Mar 2014

American College of Cardiology honors two Cedars-Sinai Heart Institute researchers

Two Cedars-Sinai Heart Institute physician-researchers have been named recipients of prestigious awards from the American College of Cardiology.

28 Mar 2014

Takeda to present results from global EXAMINE CV safety outcomes trial at ACC 2014

Takeda Pharmaceuticals Company Limited will present sub-analyses from the global EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) cardiovascular (CV) safety outcomes trial in a poster session at the American College of Cardiology’s 63rd Annual Scientific Session in Washington, DC.

28 Mar 2014

$Patrys reports final results from PAT-SM6 Phase I/IIa study in patients with refractory or relapsed MM$

Patrys reports final results from PAT-SM6 Phase I/IIa study in patients with refractory or relapsed MM

Patrys Limited, a clinical stage biotechnology company, is pleased to announce the final results from its Phase I/IIa, open-label study in patients with refractory or relapsed multiple myeloma (MM).

28 Mar 2014

Novartis’ investigational compound achieves overall response rate of 58% in patients with ALK+ NSCLC

Novartis today announced that The New England Journal of Medicine (NEJM) published clinical trial results showing the investigational compound LDK378 (ceritinib) achieved an overall response rate (ORR, including complete response [CR] and partial response [PR]) of 58% and a median progression-free survival (PFS) of seven months in adults with advanced anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) who received 400 mg or higher of LDK378 per day.

28 Mar 2014

FDA accepts AVP-825 NDA for acute treatment of migraine

The U.S. Food and Drug Administration has accepted the New Drug Application (NDA) for AVP-825, an innovative closed-palate Breath Powered investigational drug-device combination product for the acute treatment of migraine.

27 Mar 2014

Cytrx releases statement in response to two recent lawsuits

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today issued the following statement in response to two recent lawsuits filed in the name of CytRx shareholders:

27 Mar 2014

Senhwa Biosciences to present CX-5461 study results at AACR meeting

Senhwa Biosciences, Inc. announced today that results from research with its first-in-class Pol I inhibitor, CX-5461, will be presented at the 2014 American Association for Cancer Research (AACR) annual meeting held on April 5-9 in San Diego, CA.

27 Mar 2014

pSivida resubmits New Drug Application for ILUVIEN

pSivida Corp., a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the New Drug Application for ILUVIEN for the treatment of chronic Diabetic Macular Edema has been resubmitted to the U.S. Food and Drug Administration (FDA).

27 Mar 2014

SAGE Therapeutics doses first patient in SAGE-547 Phase 1/2 trial for treatment of SRSE

SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat life-threatening and rare central nervous system (CNS) disorders, today announced dose initiation of the first patient in a Phase 1/2 clinical trial of SAGE-547, a neuroactive steroid, in super-refractory status epilepticus (SRSE), a critical condition in which the brain is in a state of persistent seizure.

27 Mar 2014

Echo Therapeutics reports net loss of $3.9M in fourth quarter 2013

Echo Therapeutics, Inc., a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced financial results for the year ended December 31, 2013.

27 Mar 2014

Experimental vaccine for HSV-2 infection reduces rate of viral shedding at 6 months

Updated Phase 1/2a results with GEN-003, a vaccine candidate under development by Genocea Biosciences, Inc. (Nasdaq: GNCA) for the treatment of herpes simplex virus type 2 (HSV-2) infection, showed the experimental vaccine to generate highly significant reductions in both the number of clinical lesion days and rate of viral shedding at six months after the final vaccine dose.

27 Mar 2014

Study seeks to adapt multi-family group treatment approach for people with spinal cord injury

Every year, more than 12,000 Americans-mostly young men-suffer spinal cord injuries in car crashes, falls, sports and acts of violence. Those dealing with this life-changing condition may soon have a better way to cope, thanks to a new collaborative research project by Washington State University Spokane and St. Luke's Rehabilitation Institute.

27 Mar 2014

Clinical Trial News and Research

ATHENA develops surrogate organ system for toxicity testing

RXi Pharmaceuticals provides business update, reports Q4 and full year 2013 financial results

Two doses of HPV-16/18 AS04-adjuvanted vaccine Cervarix non-inferior to three-doses

Idera Pharmaceuticals reports positive top-line results from Phase 2 trial of IMO-8400

ADMA Biologics reports consolidated net loss of $15.5M in 2013

American College of Cardiology honors two Cedars-Sinai Heart Institute researchers

Takeda to present results from global EXAMINE CV safety outcomes trial at ACC 2014

Patrys reports final results from PAT-SM6 Phase I/IIa study in patients with refractory or relapsed MM

Novartis’ investigational compound achieves overall response rate of 58% in patients with ALK+ NSCLC

FDA accepts AVP-825 NDA for acute treatment of migraine

Cytrx releases statement in response to two recent lawsuits

Senhwa Biosciences to present CX-5461 study results at AACR meeting

pSivida resubmits New Drug Application for ILUVIEN

SAGE Therapeutics doses first patient in SAGE-547 Phase 1/2 trial for treatment of SRSE

Echo Therapeutics reports net loss of $3.9M in fourth quarter 2013

Experimental vaccine for HSV-2 infection reduces rate of viral shedding at 6 months

Study seeks to adapt multi-family group treatment approach for people with spinal cord injury

EORTC study does not support combination chemotherapy for soft tissue sarcoma

Egalet provides business update, reports full year 2013 financial results

Mast Therapeutics reports net loss of $5.7 million for fourth quarter 2013

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer